Jachimowicz, Ron D. , Beleggia, Filippo , Isensee, Joerg , Velpula, Bhagya Bhavana , Goergens, Jonas , Bustos, Matias A. , Doll, Markus A. , Shenoy, Anjana , CHECA RODRIGUEZ, CINTIA, Wiederstein, Janica Lea , Baranes-Bachar, Keren , Bartenhagen, Christoph , Hertwig, Falk , Teper, Nizan , Nishi, Tomohiko , Schmitt, Anna , Distelmaier, Felix , Luedecke, Hermann-Josef , Albrecht, Beate , Krueger, Marcus , Schumacher, Bjorn , Geiger, Tamar , Hoon, Dave S. B. , Huertas, Pablo , Fischer, Matthias , Hucho, Tim , Peifer, Martin , Ziv, Yael , Reinhardt, H. Christian , Wieczorek, Dagmar , Shiloh, Yosef
No
Cell
Article
Científica
38.637
24.698
24/01/2019
000456526100012
Genomic instability can be a hallmark of both human genetic disease and cancer. We identify a deleterious UBQLN4 mutation in families with an autosomal recessive syndrome reminiscent of genome instability disorders. UBQLN4 deficiency leads to increased sensitivity to genotoxic stress and delayed DNA double-strand break (DSB) repair. The proteasomal shuttle factor UBQLN4 is phosphorylated by ATM and interacts with ubiquitylated MRE11 to mediate early steps of homologous recombination-mediated DSB repair (HRR). Loss of UBQLN4 leads to chromatin retention of MRE11, promoting non-physiological HRR activity in vitro and in vivo. Conversely, UBQLN4 overexpression represses HRR and favors non-homologous end joining. Moreover, we find UBQLN4 overexpressed in aggressive tumors. In line with an HRR defect in these tumors, UBQLN4 overexpression is associated with PARP1 inhibitor sensitivity. UBQLN4 therefore curtails HRR activity through removal of MRE11 from damaged chromatin and thus offers a therapeutic windowfor PARP1 inhibitor treatment in UBQLN4-overexpressing tumors.